🔍

AARTIDRUGS - Aarti Drugs

📊 NSE: AARTIDRUGS 🏢 Pharmaceuticals - Indian - Bulk Drugs 📅 Last Updated: 12/13/2025 17:43

📢 Recent Corporate Announcements

Aarti Drugs to Invest ₹10 Crore in Subsidiary Pinnacle Life Science for Expansion

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 07 Mar 2026, 01:11 PM

Aarti Drugs Limited has approved an investment of ₹10 crore in its wholly-owned subsidiary, Pinnacle Life Science Private Limited, through a rights issue. The capital infusion is specifically intended to finance Pinnacle's expansion and capital expenditure plans, alongside general corporate purposes. Pinnacle is a key formulations player for the group, exporting to over 30 countries, though its turnover saw a decline to ₹253.92 crore in FY25 from ₹314.66 crore in FY24. This investment signals the parent company's commitment to strengthening its formulations business segment.

Investment of ₹10 crore via subscription to 78,125 equity shares at a price of ₹1,280 per share (including premium).
Pinnacle Life Science reported a turnover of ₹253.92 crore for FY 2024-25.
Funds will be utilized for financing expansion/capex plans and general corporate purposes.
Pinnacle operates in high-growth segments including oncology, cardiovascular, anti-infectives, and diabetics.
The share allotment is expected to be completed on or before March 20, 2026.

💡 Investors should view this as a strategic move to bolster the formulations subsidiary, though they should monitor if this capex helps reverse the recent decline in Pinnacle's annual turnover.

Aarti Drugs Expands in Chile with New Step-Down Subsidiary Tripharma Chile SpA

🟢 POSITIVE ⭐ 4/10

EXPANSION 📅 02 Mar 2026, 10:34 PM

Aarti Drugs Limited has incorporated a new step-down subsidiary, Tripharma Chile SpA, through its existing subsidiary Pinnacle Chile SpA. The new entity, incorporated on February 27, 2026, will focus on marketing formulation drugs and participating in both private and government tender markets in Chile. The initial investment is 1,000,000 Chilean Pesos for 100% shareholding. This move is aimed at strengthening the company's pharmaceutical footprint in the Latin American region.

Incorporation of Tripharma Chile SpA as a 100% owned step-down subsidiary in Chile
Initial share capital contribution of 1,000,000 Chilean Pesos for 1,000,000 shares
Business focus includes marketing formulation drugs and participating in Chilean tenders
The new entity's operations are aligned with the core pharmaceutical business of the parent company

💡 Investors should view this as a positive step toward international market penetration, though the immediate financial impact is likely to be marginal given the small initial capital.

Aarti Drugs Q3 FY26: PAT Surges 58% to ₹40.5 Cr Despite EBITDA Margin Pressure

🔵 WATCH ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 08:46 PM

Aarti Drugs reported a mixed performance for Q3 FY26, with consolidated revenue growing 8% YoY to ₹602.9 crores and PAT surging 58% to ₹40.5 crores. However, EBITDA declined 10% YoY to ₹56.3 crores with margins contracting to 9.3% due to weak antibiotic demand, supply chain disruptions from China, and one-time plant shutdowns for refurbishment. The formulations segment was a bright spot, growing 58% YoY, driven by strong export demand. Management expects significant margin improvement as the new Sayakha facility ramps up from 30% to 50% utilization by April 2026.

Consolidated revenue increased 8% YoY to ₹602.9 crores, while PAT rose 58% to ₹40.5 crores.
Formulations segment revenue grew 58% YoY to ₹76.6 crores, with exports accounting for 67% of segment sales.
The Sayakha greenfield facility achieved 30% utilization in its first quarter, targeting 50% by April 2026.
Operational headwinds including plant shutdowns and ramp-up costs impacted PBT by approximately ₹14-15 crores.
First oncology product commercialization is scheduled for Q4 FY26, with oncology expected to contribute 40% of formulation revenue in 3 years.

💡 Investors should focus on the successful ramp-up of the Sayakha facility and the commercialization of the oncology pipeline in Q4 as key triggers for margin recovery. While short-term margins are under pressure, the backward integration strategy is expected to add ₹50 crores to annual EBITDA at full scale.

Aarti Drugs to Attend Investor Conferences on Feb 10 and Feb 18, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Feb 2026, 07:16 PM

Aarti Drugs Limited has announced its participation in two upcoming investor conferences in Mumbai. The first interaction is organized by Systematix on February 10, 2026, featuring 1x1 and group meetings. The second event is hosted by Dolat Capital on February 18, 2026. The company stated that discussions will be limited to publicly available information and no unpublished price sensitive information will be shared.

Investor meeting with Systematix scheduled for February 10, 2026, from 10:00 AM to 2:00 PM.
Investor meeting with Dolat Capital scheduled for February 18, 2026, from 9:00 AM to 11:00 AM.
Meetings will be held in person at Taj Santacruz and Grand Hyatt in Mumbai.
Format includes both 1x1 and group interactions with institutional investors.
Company confirms compliance with SEBI Regulation 30 regarding disclosure of information.

💡 Investors should monitor for any investor presentations or transcripts released after these meetings for updates on the company's growth outlook. No immediate trading action is required based on this routine scheduling announcement.

Aarti Drugs Schedules Investor Meetings for February 10 and February 18, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Feb 2026, 07:14 PM

Aarti Drugs Limited has announced its participation in two upcoming investor conferences in Mumbai. The first interaction is organized by Systematix on February 10, 2026, featuring 1x1 and group meetings. The second engagement is hosted by Dolat Capital on February 18, 2026, at the Grand Hyatt. The company has clarified that discussions will be limited to publicly available information and no unpublished price sensitive information will be shared.

Investor meeting with Systematix scheduled for February 10, 2026, from 10:00 am to 2:00 pm.
Investor meeting with Dolat Capital scheduled for February 18, 2026, from 9:00 am to 11:00 am.
Meetings will be held in 1x1 or group formats at Taj Santacruz and Grand Hyatt, Mumbai.
Company confirms that no unpublished price sensitive information (UPSI) will be discussed.

💡 This is a routine disclosure; investors should watch for any subsequent investor presentations or transcripts that may be released following these meetings for insights into management's outlook.

Aarti Drugs Releases Audio Recording of Q3 & 9M FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Feb 2026, 07:00 PM

Aarti Drugs Limited has made the audio recording of its Q3 and nine-month FY26 earnings conference call available to the public. The call follows the financial results announcement for the period ending December 31, 2025, which was initially intimated on January 28, 2026. Investors can access the recording via the company's official website to understand management's commentary on operational performance. A written transcript of the interaction is expected to be filed with the stock exchanges shortly.

Audio recording for the Q3 and 9M FY26 earnings call is now live on the company website.
The call covers financial performance for the period ending December 31, 2025.
A formal written transcript will be shared with BSE and NSE in due course.
The filing is a standard compliance procedure under Regulation 30 of SEBI LODR Regulations.

💡 Investors should listen to the recording or wait for the transcript to gain qualitative insights into management's outlook on API pricing and volume growth. No immediate trading action is required based on this procedural filing.

Aarti Drugs Q3 FY26: PAT Jumps 58% YoY to ₹40.5 Cr; EBITDA Margins Contract to 9.3%

🔵 WATCH ⭐ 7/10

EARNINGS 📅 03 Feb 2026, 08:06 PM

Aarti Drugs reported a mixed Q3 FY26 with revenue growing 8% YoY to ₹602.9 crore, led by strong growth in Formulations (+59%) and Specialty Chemicals (+51%). While PAT surged 58% YoY to ₹40.5 crore, operational EBITDA declined 10% YoY to ₹56.3 crore due to commissioning costs of new facilities and transient market dynamics. The company is aggressively pursuing backward integration, with its new Sayakha plant achieving 30% utilization and aiming for 100% self-reliance in Metformin intermediates within 8 months. Management indicates that pricing has reached an inflection point with improved momentum seen in January 2026.

Consolidated Revenue grew 8% YoY to ₹602.9 crore, though API segment revenue slightly declined by 1% YoY.
EBITDA margins contracted by 190 bps YoY to 9.3% due to initial absorption of commissioning costs.
Formulations segment revenue rose 59% YoY to ₹76.4 crore, with exports accounting for 67% of this segment.
Sayakha plant for methyl amines achieved 30% capacity utilization in its first quarter of operations.
9M FY26 PAT stands at ₹139.7 crore, reflecting a 49% YoY growth compared to the previous year.

💡 Investors should monitor the capacity ramp-up at the Sayakha and Tarapur facilities, as successful backward integration is key to margin recovery. While the YoY PAT growth is strong, the QoQ decline in EBITDA suggests operational pressures that need to stabilize in the coming quarters.

Aarti Drugs Q3 FY26: Revenue Up 8% to ₹603 Cr, PAT Surges 58% Aided by Tax Refund

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 03 Feb 2026, 08:02 PM

Aarti Drugs reported a steady 8% YoY revenue growth to ₹602.9 crore for Q3 FY26, driven by domestic demand and export formulations. While PAT surged 58% to ₹40.5 crore, this was significantly bolstered by a ₹16.38 crore income tax refund. Operational performance faced pressure as EBITDA fell 10% YoY to ₹56.3 crore, with margins contracting to 9.3% due to high-cost inventory consumption and temporary maintenance shutdowns. The company is making strategic progress in backward integration, with its new Sayakha facility reaching 30% capacity utilization in its first quarter.

Consolidated revenue grew 8% YoY to ₹602.9 crore, while 9M FY26 revenue reached ₹1,846.6 crore.
EBITDA margins contracted by 190 bps YoY to 9.3% due to inventory-related factors and scheduled maintenance.
PAT increased 58% YoY to ₹40.5 crore, inclusive of a one-time IT tax refund of ₹16.38 crore.
Sayakha backward integration plant achieved 30% capacity utilization; expected to reach 50% by April 2026.
API segment continues to dominate the revenue mix at 75.5%, followed by Formulations at 12.7%.

💡 Investors should monitor the ramp-up of the Sayakha and Tarapur facilities, as successful backward integration is critical for margin recovery. While the PAT growth looks high, it is heavily influenced by a tax refund, so focus should remain on core EBITDA improvements in upcoming quarters.

Aarti Drugs Q3 Net Profit Rises 9.3% YoY to ₹40.55 Cr; Declares ₹2 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 07:33 PM

Aarti Drugs reported a consolidated net profit of ₹40.55 crore for Q3 FY26, marking a 9.3% growth compared to ₹37.09 crore in the same period last year. Revenue from operations increased 8.1% YoY to ₹601.71 crore, although it saw a sequential decline from ₹652.79 crore in Q2. The company declared an interim dividend of ₹2 per share (20%) with a record date of February 9, 2026. Additionally, the company strengthened its leadership by inducting three functional heads into the Senior Management Personnel category to align with organizational growth.

Consolidated Net Profit for Q3 FY26 stood at ₹40.55 crore, up from ₹37.09 crore YoY.
Revenue from operations grew 8.1% YoY to ₹601.71 crore for the quarter ended December 31, 2025.
Declared an interim dividend of ₹2 per equity share with a record date fixed for February 9, 2026.
9M FY26 consolidated net profit reached ₹140.54 crore on a total revenue of ₹1,845.01 crore.
New manufacturing plant at Sayakha, Gujarat, which commenced operations in Sept 2025, is now contributing to production.

💡 Investors may view the YoY growth and dividend declaration positively, though the sequential dip in revenue suggests monitoring margin pressures. Focus on the scaling of the new Sayakha plant as a primary growth catalyst for the upcoming quarters.

Aarti Drugs Declares Rs 2 Interim Dividend; Sets February 9 as Record Date

🟢 POSITIVE ⭐ 6/10

DIVIDEND 📅 03 Feb 2026, 07:16 PM

Aarti Drugs Limited has announced an interim dividend of Rs 2 per equity share for the financial year 2025-26, representing a 20% payout on the face value of Rs 10. The Board of Directors approved this distribution during their meeting on February 3, 2026. The company has officially designated February 9, 2026, as the record date to identify shareholders eligible for the payment. This move reflects the company's commitment to sharing profits with its investors.

Interim dividend of Rs 2 per equity share declared for FY 2025-26
Dividend payout represents 20% of the face value of Rs 10 per share
Record date for dividend eligibility fixed as February 9, 2026
Board meeting for the declaration was held on February 3, 2026

💡 Investors seeking to receive the dividend should ensure they hold the shares before the ex-dividend date, typically one business day prior to the record date. Long-term investors may view this consistent payout as a sign of stable cash flow.

Aarti Drugs Declares ₹2 Interim Dividend; Q3 Net Profit Rises 9.4% YoY to ₹40.54 Cr

🟡 NEUTRAL ⭐ 7/10

DIVIDEND 📅 03 Feb 2026, 07:10 PM

Aarti Drugs has declared an interim dividend of ₹2 per share for FY 2025-26, setting February 9, 2026, as the record date. The company reported a consolidated net profit of ₹40.54 crore for Q3 FY26, representing a 9.4% growth year-on-year, though it saw a sequential decline from ₹45.16 crore in Q2. Revenue for the quarter stood at ₹601.71 crore, up 8.1% from the previous year's corresponding quarter. Additionally, the company highlighted the commencement of its new manufacturing plant in Sayakha, Gujarat, which began operations in September 2025.

Declared interim dividend of ₹2 per equity share (20% of face value) with a record date of February 9, 2026.
Consolidated Q3 FY26 revenue reached ₹601.71 crore, an 8.1% increase over Q3 FY25.
Net profit for the quarter grew 9.4% YoY to ₹40.54 crore, while EPS stood at ₹4.44.
New manufacturing plant at Sayakha, Gujarat, successfully commenced commercial operations on September 4, 2025.
Strengthened leadership by appointing three new functional heads to the Senior Management Personnel team.

💡 Investors should track the record date of February 9 to be eligible for the dividend and monitor the performance of the new Sayakha plant for its impact on future margins. While YoY growth is steady, the sequential decline in revenue and profit suggests a need to watch for cost pressures in the pharmaceutical segment.

Aarti Drugs Q3 Net Profit Rises 9.4% YoY to ₹40.5 Cr; Declares ₹2 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 07:05 PM

Aarti Drugs reported a consolidated revenue of ₹601.7 crore for Q3 FY26, marking an 8.1% growth compared to ₹556.6 crore in the same period last year. Net profit for the quarter increased to ₹40.5 crore from ₹37.1 crore YoY, although it saw a sequential decline from ₹45.2 crore in Q2 FY26. The company declared an interim dividend of ₹2 per share (20%) with a record date of February 9, 2026. Performance was supported by the commencement of the new Sayakha, Gujarat plant earlier in the fiscal year.

Consolidated Revenue from operations stood at ₹601.7 crore, up 8.1% YoY but down 7.8% QoQ.
Net Profit for the quarter reached ₹40.5 crore, a 9.4% increase over the previous year's ₹37.1 crore.
Interim dividend of ₹2 per equity share declared with a total payout of approximately ₹18.25 crore.
New manufacturing facility at Sayakha, Gujarat, which started in September 2025, is now contributing to operations.
Three functional heads in Marketing, Export Marketing, and Purchase elevated to Senior Management Personnel.

💡 Investors may find the YoY growth and dividend declaration encouraging, though the sequential dip in profitability suggests monitoring margin pressures. Focus should remain on the volume ramp-up from the new Sayakha plant in the upcoming quarters.

Aarti Drugs Credit Rating Reaffirmed at AA-/Stable for Rs 1,768 Cr Facilities

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 29 Jan 2026, 08:17 PM

CRISIL has reaffirmed the credit ratings for Aarti Drugs Limited's bank facilities totaling Rs. 1,768 Crores. The long-term rating is maintained at 'CRISIL AA-/Stable', and the short-term rating is reaffirmed at 'CRISIL A1+'. This reaffirmation suggests that the company maintains a healthy credit profile and sufficient liquidity to meet its financial obligations. The stable outlook indicates that the rating agency expects the company to maintain its business and financial risk profile over the medium term.

CRISIL reaffirmed the Long-Term Rating at 'CRISIL AA-/Stable' for bank facilities.
Short-Term Rating reaffirmed at 'CRISIL A1+', the highest category for short-term instruments.
Total bank loan facilities covered under this rating amount to Rs. 1,768 Crores.
The rating action reflects the company's established position in the pharmaceutical industry.

💡 The reaffirmation of credit ratings is a positive sign of financial stability, but since there is no upgrade, the impact on the stock price is likely to be neutral. Investors should maintain their positions and focus on upcoming quarterly results for growth triggers.

Aarti Drugs to Host Q3 & 9M FY26 Earnings Conference Call on February 4, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 28 Jan 2026, 09:42 PM

Aarti Drugs Limited has scheduled its quarterly earnings conference call for Wednesday, February 4, 2026, at 11:00 AM IST. The management will discuss the company's financial performance for the third quarter and nine-month period ending December 31, 2025. Key attendees include the Joint Managing Director, CFO, and the Managing Director of Pinnacle Life Science. This call provides an opportunity for investors to gain insights into the company's operational trajectory and future outlook.

Earnings conference call scheduled for February 4, 2026, at 11:00 AM IST.
Focus on financial results for Q3 FY26 and the nine-month period ended December 31, 2025.
Senior management including Jt. MD Harshit Savla and CFO Adhish Patil will be present.
Dial-in details provided for major global hubs including USA, UK, Singapore, and Hong Kong.

💡 Investors should track the Q3 results release prior to the call and listen to management commentary regarding raw material pricing and demand trends in the API sector.

Aarti Drugs Submits SEBI Compliance Certificate for Q3 FY2025-26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 07:02 PM

Aarti Drugs Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Intime India Private Limited, confirms the processing of dematerialization requests for the quarter ended December 31, 2025. It verifies that security certificates received were mutilated, cancelled, and the name of depositories substituted in the register of members. This is a standard procedural filing ensuring the company remains in compliance with Indian regulatory standards.

Compliance certificate submitted for the quarter ended December 31, 2025
Issued by Registrar and Transfer Agent, MUFG Intime India Private Limited
Confirms dematerialization requests were processed and listed on stock exchanges
Verification that physical certificates were mutilated and cancelled as per SEBI norms

💡 This is a routine administrative filing with no impact on company fundamentals. No action is required from investors based on this specific announcement.

View All AARTIDRUGS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Therapeutic-wise revenue within the API segment for Q2 FY26: Anti-biotic (36.1%), Anti-protozoal (18.8%), Anti-diabetic (15.3%), Anti-inflammatory (11.8%), Anti-fungal (11.7%), and Others (6.4%). Consolidated revenue for FY 2024-25 was INR 2,403.4 Cr, reflecting a 5% YoY decline.

Geographic Revenue Split

Export demand remained robust in Q2 FY26, offsetting soft domestic demand trends, particularly in the antibiotics category. Specific regional percentage splits were not disclosed in the available documents.

Profitability Margins

Consolidated PAT margin for FY 2024-25 was 7.0% (INR 168.1 Cr). For Q2 FY26, the PAT margin was 6.9% (INR 45 Cr), up from 5.8% (INR 35 Cr) in Q2 FY25. Gross margin for Q2 FY26 improved to 37.5%, up 310 bps YoY.

EBITDA Margin

EBITDA margin for FY 2024-25 was 12.6% (INR 303.4 Cr). For Q2 FY26, EBITDA margin improved to 12.9% (INR 84.4 Cr), a 23% YoY increase in absolute EBITDA and a 150 bps margin improvement.

Capital Expenditure

A capex program of INR 600 Cr is nearly complete. During Q2 FY26, the company incurred capex of approximately INR 45.6 Cr to boost capacity and margins.

Credit Rating & Borrowing

CRISIL ratings reflect an established market position and strong financial risk profile. Finance costs for FY 2024-25 were INR 35.87 Cr (Consolidated). The Debt-Equity ratio stood at 0.45 as of March 31, 2025.

⚙️ Operational Drivers

Raw Materials

Specific raw materials include Amines (for the Sayakha facility) and inputs for Metformin. COGS for Q2 FY26 was INR 408.3 Cr, representing approximately 62.5% of net revenue.

Capacity Expansion

The Sayakha amines facility was commissioned in September 2025 as a pivotal step in backward integration. Future growth is driven by two Greenfield projects and ongoing Brownfield expansions.

Raw Material Costs

COGS for H1 FY26 was INR 781.7 Cr compared to INR 753.8 Cr in H1 FY25. The company uses backward integration to mitigate susceptibility to raw material price fluctuations.

Manufacturing Efficiency

Manufacturing efficiency is driven by de-bottlenecking and continuous technological enhancement. Capacity utilization is expected to improve as new capacities contribute meaningfully.

Logistics & Distribution

The company maintains an expansive and resilient distribution system, though specific costs as a percentage of revenue were not disclosed.

📈 Strategic Growth

Expected Growth Rate

15%

Growth Strategy

Growth will be achieved through backward integration (Sayakha amines facility), capacity expansion (Greenfield and Brownfield projects), and a target to return consolidated EBITDA margins to 15-16% sequentially. The company is also evaluating a new product portfolio for the next 5-10 years to grow revenue from INR 5,000 Cr to INR 10,000 Cr.

Products & Services

Active Pharmaceutical Ingredients (APIs) including Metformin, Antibiotics, Anti-protozoals, Anti-inflammatory, Anti-fungal drugs, and Formulations (via Pinnacle Life Science).

Brand Portfolio

Aarti Drugs Limited, Pinnacle Life Science Private Limited.

New Products/Services

The company is in early-phase discussions to enter the GLP-1 (anti-diabetic) market with intermediaries or APIs, targeting long-term growth over the next 5-10 years.

Market Expansion

Focusing on robust export demand to offset domestic weakness. Target regions include developed markets with stringent quality and compliance requirements.

🌍 External Factors

Industry Trends

The industry faces high R&D costs and long gestation periods. Current trends show soft domestic demand in antibiotics but robust export demand. The company is positioning for future growth in GLP-1 and amines.

Competitive Landscape

The industry is highly competitive with intense competition from both domestic and international players.

Competitive Moat

Durable advantages include cost leadership through backward integration and long-standing client relationships. These are sustainable due to high entry barriers in complex manufacturing.

Macro Economic Sensitivity

Sensitive to changes in economic conditions, government policies, and regulatory environments. CRISIL notes susceptibility to raw material price volatility.

Consumer Behavior

Shift in demand trends showing softness in the domestic antibiotics category while export demand remains strong.

Geopolitical Risks

The company is navigating geopolitical challenges in the broader operating environment which necessitate a focus on operational resilience.

⚖️ Regulatory & Governance

Industry Regulations

Operations must meet stringent quality and compliance requirements of domestic and international regulators (e.g., pollution norms, manufacturing standards).

Environmental Compliance

The company has shifted to eco-friendly packaging (paper bags, fibre drums) and maintains an EcoVadis score in the 89th percentile globally.

Taxation Policy Impact

Total tax expenses for FY 2024-25 were INR 43.67 Cr on a consolidated PBT of INR 211.77 Cr, representing an effective tax rate of approximately 20.6%.